US · Healthcare · Biotechnology
EPS came in at -0.89 against a street estimate of -0.68 — a miss of 30.9%.
Analysts rate Evommune, Inc. a buy (9 buy, 2 hold, 0 sell out of 11) with an average price target of $22.33.
| Fund | Stake |
|---|---|
| EQT Fund Management S.à r.l. | 14.57% |
| RA Capital Management, LLC | 9.63% |
| T. Rowe Price Associates, Inc. | 5.35% |
| Pivotal bioVenture Partners Investment Advisor LLC | 5.31% |
| JPMorgan Chase & Co | 4.28% |
| RTW INVESTMENTS, LLC | 4.14% |
| Nan Fung Group Holdings Ltd | 3.97% |
| Point72 Asset Management, L.P. | 3.95% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Evommune, Inc. — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.